MRD and post-transplant outcomes in older AML patients, enhancer hijacking in a novel high-risk B-other ALL subtype, and ruxolitinib in pediatric HLH

In this week’s episode we will discuss new data demonstrating that, in older patients with AML, post-transplant relapse risk is driven by clinical and molecular features present at diagnosis, but not remission MRD.  We’ll also explore two studies that characterize a novel high-risk B-ALL subtype, defined by two unique genomic alterations that includes a deletion resulting in enhancer hijacking that deregulates expression of the CDX2 homeobox transcription factor. Finally, we’ll review results of a large, single-arm phase 2 trial providing encouraging clinical evidence for the use of ruxolitinib as a front-line treatment for pediatric hemophagocytic lymphohistiocytosis.

Released June 16, 2022

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

The articles highlighted in this episode are listed below:

• Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

  Authors: H. Moses Murdock, Haesook T. Kim, Nathan Denlinger, Pankit Vachhani, Bryan Hambley, Bryan S. Manning, Shannon Gier, Christina Cho, Harrison K. Tsai, Shannon McCurdy, Vincent T. Ho, John Koreth, Robert J. Soiffer, Jerome Ritz, Martin P. Carroll, Sumithira Vasu, Miguel-Angel Perales, Eunice S. Wang, Lukasz P. Gondek, Steven Devine, Edwin P. Alyea, III, R. Coleman Lindsley, Christopher J. Gibson

• Transplant in older adults with AML: genomic wheat and chaff

  Authors : Sylvie D. Freeman, Peter Valk

• Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

  Authors: Marie Passet, Rathana Kim, Stéphanie Gachet, François Sigaux, Julie Chaumeil, Ava Galland, Thomas Sexton, Samuel Quentin, Lucie Hernandez, Lise Larcher, Hugo Bergugnat, Tao Ye, Nezih Karasu, Aurélie Caye, Beate Heizmann, Isabelle Duluc, Patrice Chevallier, Philippe Rousselot, Françoise Huguet, Thibaut Leguay, Mathilde Hunault, Françoise Pflumio, Jean-Noël Freund, Camille Lobry, Véronique Lhéritier, Hervé Dombret, Claire Domon-Dell, Jean Soulier, Nicolas Boissel, Emmanuelle Clappier

• Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

  Authors: Shunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, Yaqi Zhao, Qingsong Gao, Elisabeth M. Paietta, Claudia Haferlach, A. Douglas Laird, Paul E. Mead, Zhaohui Gu, Wendy Stock, Mark Litzow, Jacob M. Rowe, Selina M. Luger, Stephen P. Hunger, Georgina L. Ryland, Breon Schmidt, Paul G. Ekert, Alicia Oshlack, Sean M. Grimmond, Jacqueline Rehn, James Breen, David Yeung, Deborah L. White, Ibrahim Aldoss, Elias J. Jabbour, Ching-Hon Pui, Manja Meggendorfer, Wencke Walter, Wolfgang Kern, Torsten Haferlach, Samuel Brady, Jinghui Zhang, Kathryn G. Roberts, Piers Blombery, Charles G. Mullighan

• Why B(-)other? About the gap of unknowns in ALL

  Author: Thoas Fioretos

• A study of ruxolitinib response–based stratified treatment for pediatric hemophagocytic lymphohistiocytosis

  Authors: Qing Zhang, Yun-Ze Zhao, Hong-Hao Ma, Dong Wang, Lei Cui, Wei-Jing Li, Ang Wei, Chan-Juan Wang, Tian-You Wang, Zhi-Gang Li, Rui Zhang

• HLH treatment: smarter, not harder

  Authors: Lauren A. Henderson, Barbara A. Degar